- You can view the full AstraZeneca Ratings Report.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.
The company has spent $600 million weighing a potential breakup.
Jefferies increased AstraZeneca's (AZN) stock rating to 'buy' this morning.